Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04273737 · ClinicalTrials.gov registry record · Phase 4
Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT04273737 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 11 participants.
The verdict
NCT04273737, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Cerebral palsy (CP) is a common childhood-onset disability associated with motor and cognitive impairments, however most research is focused on motor outcomes. The aim of this study is to determine the effects of Amantadine, a dopaminergic agonist, on cognitive function in adolescents and adults with CP.
Interventions
- DRUG Amantadine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-02-28 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04273737
The ClinicalTrials.gov registry entry for NCT04273737 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amantadine Hydrochloride is the first listed.
NCT04273737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04273737 about?
NCT04273737 is a clinical study titled "Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy". Cerebral palsy (CP) is a common childhood-onset disability associated with motor and cognitive impairments, however most research is focused on motor outcomes. The aim of this study is to determine the effects of Amantadine, a dopaminergic agonist, on cognitive function in adolescents and adults wit...
What is the current status of trial NCT04273737?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2020-02-28. Estimated completion is 2022-02-22.
What interventions are being tested in trial NCT04273737?
The interventions under investigation include: Amantadine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04273737?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.